Catalog No.
VXX52601
Species reactivity
Plasmodium vivax (malaria parasite P. vivax)
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Ookinete surface protein, Ookinete surface protein Pvs25, Pvs25
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O96555
Applications
ELISA, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
2A8
Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax., PMID:39033079
Immunogenicity of PvCyRPA, PvCelTOS and Pvs25 chimeric recombinant protein of Plasmodium vivax in murine model., PMID:38962015
A two-dose viral-vectored Plasmodium vivax multistage vaccine confers durable protection and transmission-blockade in a pre-clinical study., PMID:38745665
A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax., PMID:38092803
Construction, Expression, and Evaluation of the Naturally Acquired Humoral Immune Response against Plasmodium vivax RMC-1, a Multistage Chimeric Protein., PMID:37511330
Naturally acquired antibodies to gametocyte antigens are associated with reduced transmission of Plasmodium vivax gametocytes to Anopheles arabiensis mosquitoes., PMID:36726645
Transdermal Transmission Blocking Vaccine for Malaria using a Solid-in-Oil Dispersion., PMID:36334812
Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination., PMID:33478283
A Multi-Stage Plasmodium vivax Malaria Vaccine Candidate Able to Induce Long-Lived Antibody Responses Against Blood Stage Parasites and Robust Transmission-Blocking Activity., PMID:31119106
Plasmodium vivax ookinete surface protein (Pvs25) is highly conserved among field isolates from five different regions of the Brazilian Amazon., PMID:31077839
The shape of the iceberg: quantification of submicroscopic Plasmodium falciparum and Plasmodium vivax parasitaemia and gametocytaemia in five low endemic settings in Ethiopia., PMID:28253867
Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax., PMID:27177945
Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization., PMID:25765968
Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites., PMID:25092912
Tricomponent complex loaded with a mosquito-stage antigen of the malaria parasite induces potent transmission-blocking immunity., PMID:24521783
Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate., PMID:22245309
Structure of Fab fragment of malaria transmission blocking antibody 2A8 against P. vivax P25 protein., PMID:22037467
Comparison of the antibody responses to Plasmodium vivax and Plasmodium falciparum antigens in residents of Mandalay, Myanmar., PMID:21819610
Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development., PMID:21807905
Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine., PMID:21315699
Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission., PMID:20637303
Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection., PMID:19752035
Plasmodium berghei ookinetes glide and release Pbs25 and circumsporozoite thrombospondin-related protein on solid surface substrata., PMID:19747017
Structure and mechanism of a transmission blocking vaccine candidate protein Pfs25 from P. falciparum: a molecular modeling and docking study., PMID:19032156
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51., PMID:18612426
Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720., PMID:17883455
Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer., PMID:17686163
The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms., PMID:16327807
Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein., PMID:16291764
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria., PMID:15837212
The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites., PMID:15618165
Preparation, crystallization and preliminary X-ray analysis of a complex between the Plasmodium vivax sexual stage 25 kDa protein Pvs25 and a malaria transmission-blocking antibody Fab fragment., PMID:15502325
Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy., PMID:15297075
Crystallization and preliminary X-ray analysis of the Plasmodium vivax sexual stage 25 kDa protein Pvs25, a transmission-blocking vaccine candidate for malaria., PMID:15039560
Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates., PMID:14695092
Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes., PMID:12804841
Transmission-blocking vaccine of vivax malaria., PMID:12543142
Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials., PMID:12071703
Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism., PMID:11738740
Current developments in malaria transmission-blocking vaccines., PMID:11727498
Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes., PMID:11083773
For research use only. Not for human or drug use.
